Johnson & Johnson Acquisitions in Cardiovascular Devices
In December 2022, Johnson & Johnson acquisitions made a significant splash in the medtech industry when the company committed $16.6 billion to acquire Abiomed—a move that would mark the beginning of a high-profile series of acquisitions aimed at solidifying their position in the high-risk cardiac intervention space. This acquisition was more than just a financial transaction; it signified the company’s strategic approach to tapping into the rapidly growing cardiovascular devices market. For more information visit https://justpaste.it/cwqc3
Comment
Share
